VITEKTA
LOE ApproachingNDAORALTABLET
Approved
Sep 2014
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VITEKTA is an oral small-molecule antiviral tablet approved by the FDA in September 2014 as an NDA. The drug's specific mechanism of action and approved indications are not detailed in available data, but its antiviral classification and Gilead Sciences sponsorship suggest HIV or hepatitis treatment. It represents a mature product in Gilead's portfolio with established market presence.
LOE Approaching6mo to LOE
Product faces imminent loss of exclusivity (April 2027), likely requiring transition from growth-focused teams to defensive strategy and cost management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on VITEKTA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.